Progesterone vs Progestin: What Every Woman on HRT Needs to Know

What Is the Difference Between Progesterone and a Progestin?

Progesterone is a single steroid molecule your ovaries produce. Micronized progesterone (brand name Prometrium) replicates that exact molecular structure. Progestins are laboratory-designed compounds that bind progesterone receptors but carry different side chains, resulting in distinct activity at androgen, glucocorticoid, and mineralocorticoid receptors.

That structural difference is not trivial. Medroxyprogesterone acetate (MPA), the progestin used in the Women's Health Initiative combined-hormone arm, has measurable glucocorticoid and androgenic partial-agonist activity that natural progesterone does not [1]. Norethindrone acetate binds androgen receptors at concentrations achieved during standard HRT dosing. Levonorgestrel, used in the Mirena IUD and some combined pills, is among the most androgenic of the commonly prescribed progestins.

Because each progestin has its own receptor fingerprint, the risks and tolerability profiles of the various compounds are not interchangeable. A woman who had side effects on norethindrone-containing combined oral contraceptives may tolerate micronized progesterone well, and vice versa.

The Endocrine Society's 2022 clinical practice guideline on menopause states: "Micronized progesterone has a more favorable metabolic and vascular profile than most synthetic progestins and is preferred when a progestogen is needed in postmenopausal women without contraindications." [2]

Why Any Progestogen Is Required in HRT

Estrogen stimulates endometrial cell proliferation. Without adequate progestogen opposition, that proliferation can progress through hyperplasia to endometrial adenocarcinoma, a sequence well documented since the 1970s [3].

Women who still have a uterus must take a progestogen alongside systemic estrogen therapy. The one exception: women who have had a hysterectomy can use estrogen alone, and that matters for risk interpretation because the WHI estrogen-alone arm (conjugated equine estrogens without MPA) showed a breast-cancer hazard ratio of 0.77 after 7.2 years of follow-up [4].

Dose and duration of progestogen exposure drive endometrial protection. The standard regimens are:

• Cyclic (sequential) regimen: Prometrium 200 mg/day for 12 to 14 consecutive days per calendar month. This induces a withdrawal bleed, which many perimenopausal women prefer because it confirms shedding.
• Continuous combined regimen: Prometrium 100 mg/day every day. Bleeding typically stops within 3 to 6 months, preferred by fully postmenopausal women.

Inadequate duration (fewer than 10 days/cycle at any dose) does not reliably prevent hyperplasia [5].

The WHI Data: What It Actually Showed About MPA

The Women's Health Initiative remains the largest randomized controlled trial of hormone therapy in postmenopausal women. The estrogen-plus-progestin arm enrolled 16,608 women (ages 50 to 79) and assigned them to conjugated equine estrogens 0.625 mg plus MPA 2.5 mg daily or matching placebo [6].

The trial was stopped early at a mean 5.6 years of follow-up. Key findings:

• Invasive breast cancer: hazard ratio 1.26 (95% CI 1.00 to 1.59) in the hormone arm [6].
• Coronary heart disease: HR 1.29 (95% CI 1.02 to 1.63) in the hormone arm [6].
• Venous thromboembolism: HR 2.11 (95% CI 1.58 to 2.82) [6].
• Colorectal cancer: HR 0.63 (95% CI 0.43 to 0.92), a protective signal [6].

Critics of the WHI note that the average participant age was 63, more than a decade past the typical menopause transition, which complicates extrapolation to women who start HRT in their late 40s or early 50s. The "timing hypothesis" or "window of opportunity" framework holds that cardiovascular benefit requires starting therapy closer to menopause onset, a concept supported by re-analyses of the WHI data stratified by age at initiation [7].

Regardless of timing debate, the MPA signal for breast cancer has been replicated observationally. The Million Women Study (N=1,084,110) found that current users of estrogen-progestogen combinations had a relative risk of 2.00 (95% CI 1.91 to 2.09) vs never users, compared with 1.30 (95% CI 1.22 to 1.38) for estrogen-alone users [8]. The progestogen type mattered: MPA and norethisterone were associated with higher relative risks than tibolone or progesterone-containing regimens in that cohort.

Micronized Progesterone and Breast Cancer Risk: What the Data Show

The E3N cohort study from France followed 80,377 women for a mean 8.1 years and provides the most detailed progestogen-type breakdown available [9]. Women using estrogen plus micronized progesterone did not have a statistically significant increase in breast-cancer risk (RR 1.00 to 95% CI 0.83 to 1.22), while those using estrogen plus a synthetic progestin did (RR 1.69 to 95% CI 1.50 to 1.91) [9].

These are observational data and carry all the limitations of that study design, including healthy-user bias. No randomized controlled trial has directly compared micronized progesterone with MPA on breast-cancer incidence as a primary endpoint. The CECELIA trial and ongoing French CLIMVIE study may close that gap, but results are not yet published.

Still, the NAMS 2022 Position Statement on hormone therapy acknowledges: "Some data suggest that micronized progesterone and dydrogesterone may be associated with a lower risk of breast cancer than other progestogens, though evidence remains insufficient to make definitive recommendations." [10]

HealthRX Progestogen Selection Framework (for discussion with your prescriber)

| Clinical scenario | Preferred progestogen | Rationale | |---|---|---| | Uterus intact, no cardiovascular risk factors, priority on breast safety signal | Micronized progesterone (Prometrium) | Most favorable observational breast-cancer data; no androgenic activity | | Uterus intact, heavy perimenopausal bleeding | Norethindrone acetate or levonorgestrel IUD | Greater endometrial atrophy effect; controls bleeding | | Uterus intact, poor sleep, anxiety | Micronized progesterone oral at bedtime | Allopregnanolone metabolite has GABA-A agonist effect; sedating | | Post-hysterectomy | No progestogen required | Estrogen alone is appropriate | | Active or recent VTE | LNG-IUD with transdermal estradiol | Minimal systemic progestogen exposure |

This framework is a clinical discussion aid, not a prescription. Individual contraindications and preferences apply.

Oral vs Transdermal Estradiol: Why the Route Matters for Clot Risk

Progesterone vs progestin is one axis of HRT decision-making. The estrogen delivery route is another, and the two interact on risk.

Oral estrogen undergoes first-pass hepatic metabolism. This upregulates hepatic production of clotting factors (factors VII, VIII, X) and C-reactive protein, and suppresses antithrombin III [11]. Transdermal estradiol, absorbed directly through skin into the systemic circulation, bypasses this hepatic effect entirely.

The ESTHER study (N=881) found that oral estrogen use was associated with a 4-fold increase in VTE risk vs non-use (OR 4.2 to 95% CI 1.5 to 11.6), while transdermal estradiol was not associated with increased VTE risk (OR 0.9 to 95% CI 0.5 to 1.6) [12]. This difference has been replicated in the QResearch UK database analysis (N=10,562 VTE cases), where oral HRT carried an adjusted OR of 2.5 vs no HRT compared with OR 0.93 for transdermal use [13].

For women with personal or family history of VTE, obesity (BMI <35 kg/m² is not the cutoff for concern; any elevated BMI increases clot risk), or known thrombophilia, transdermal estradiol is the evidence-based first choice.

Patch vs Gel: Comparing Transdermal Estradiol Delivery Options

Both patches and gels deliver estradiol transdermally. The practical differences come down to adhesion, flexibility, and serum-level consistency.

Estradiol patches are available as matrix patches (Vivelle-Dot, Climara) changed once or twice weekly. Matrix patches have largely replaced reservoir patches because of lower gel-leakage rates. Twice-weekly patches (Vivelle-Dot 0.025 to 0.1 mg/day) maintain fairly steady serum estradiol levels with modest peaks and troughs. The Climara once-weekly patch shows somewhat larger intra-individual variability over the 7-day wear period [14].

Estradiol gels (Divigel 0.1%, EstroGel 0.06%) are applied daily to a defined skin area. Daily application keeps serum estradiol levels more consistent than a twice-weekly patch because the dosing interval is shorter. A pharmacokinetic study of Divigel 0.1% (estradiol gel 1 g/day) achieved mean steady-state serum estradiol of approximately 40 pg/mL, within the therapeutic target range of 40 to 100 pg/mL for most symptomatic women [15].

Both gel and patch are appropriate for women seeking to avoid oral first-pass effects. The choice is personal: some women find daily gel application easier to remember than twice-weekly patch changes; others prefer not to apply gel to clothing-exposed skin in summer. Transfer to a partner or child remains a real concern with gels, particularly if application is not allowed to dry for 2 minutes before covering.

Compounded vs FDA-Approved Progesterone

Compounded hormones are mixed in a pharmacy rather than manufactured to FDA standards. They are legal and occasionally necessary (a documented allergy to Prometrium's peanut oil base is one example), but they do not carry FDA-reviewed evidence for dosing accuracy, bioavailability, sterility, or endometrial protection.

The FDA's 2008 warning letter to compounding pharmacies and subsequent 2019 guidance specifically flagged estriol and combinations not approved as finished drug products. The agency states that compounded drugs "lack FDA approval" and that "patients and prescribers should be aware that the safety, effectiveness, and quality of compounded drugs have not been established." [16]

A practical concern: commercially available Prometrium has a published bioavailability of approximately 10% due to extensive first-pass metabolism from the oral route, but this is factored into the approved dose. Compounded "bioidentical" creams often use non-standard routes (transdermal or vaginal) with unknown endometrial absorption. A 2018 study published in Menopause (N=57 women) found that commercially available compounded progesterone cream at doses intended to protect the endometrium produced serum progesterone levels of 0.8 ng/mL compared with 4.9 ng/mL for oral Prometrium 200 mg, insufficient to reliably oppose estrogen's proliferative effect [17].

The North American Menopause Society's guidance is explicit: "Compounded bioidentical hormones should not be used instead of FDA-approved hormone therapy unless a specific medical need exists that cannot be met by approved products." [10]

Side-Effect Comparison: Progesterone vs Common Progestins

Side-effect profiles vary substantially between progestogen types, and patient tolerability is a legitimate clinical reason to switch.

Micronized progesterone (Prometrium):

• Sedation and dizziness (allopregnanolone metabolite acts on GABA-A receptors). Taking at bedtime converts this side effect into a benefit for women with insomnia.
• Minimal androgenic effects: no acne, hair thinning, or lipid worsening in clinical doses.
• Peanut oil base: contraindicated in peanut allergy.
• Mood effects are generally neutral or mildly positive in studies measuring validated depression scales [18].

Medroxyprogesterone acetate (MPA, Provera):

• Bloating and breast tenderness are commonly reported.
• Glucocorticoid activity may contribute to weight gain and glucose intolerance at standard doses.
• Negative lipid effects: reduces HDL-C by approximately 5 to 8% in combined oral regimens [19].
• Associated with more negative mood ratings vs micronized progesterone in the PEPI trial [19].

Norethindrone acetate (NETA, found in Activella, FemHRT):

• Androgenic: may worsen acne or libido-related concerns in androgen-sensitive women.
• Stronger endometrial atrophy effect useful for women with heavy perimenopausal bleeding.
• At doses used in HRT (0.5 to 1 mg/day), partial conversion to ethinyl estradiol adds modest estrogenic activity.

Levonorgestrel IUD (Mirena 52 mg):

• Delivers levonorgestrel directly to the uterine cavity; systemic absorption is low (approximately 15 to 20 mcg/day).
• Used off-label with systemic transdermal estradiol as a low-systemic-progestogen HRT regimen. Evidence for endometrial protection is strong: the CHOICE trial and subsequent registry data show endometrial protection equivalent to oral progestins [20].
• Irregular spotting for the first 3 to 6 months is common.

Starting HRT: A Practical Checklist Before Your Appointment

The hormone therapy decision is not binary. It involves estrogen type, estrogen route, progestogen type, progestogen schedule, and baseline risk assessment. A few items to bring to your prescriber:

1. Personal and family history of breast cancer, VTE, or stroke. These alter the risk-benefit calculation in well-defined ways.
2. Uterine status. Post-hysterectomy women do not need a progestogen.
3. Symptom priority. Hot flashes and night sweats respond to systemic estrogen. Vaginal dryness can be addressed with local vaginal estrogen (10 mcg estradiol vaginal tablet, Vagifem) without systemic progestogen in many women.
4. Lipid and metabolic panel. Baseline fasting lipids, fasting glucose, and blood pressure before starting systemic therapy.
5. Baseline mammogram. Current US Preventive Services Task Force recommendations support biennial screening for women 40 to 74 [21].

The USPSTF notes that for women experiencing menopausal symptoms, clinicians should discuss treatment options including hormone therapy, the risks and benefits of which "should be individualized based on each woman's clinical circumstances and preferences." [21]

Most women who are healthy, under age 60, and within 10 years of menopause onset have a favorable benefit-risk profile for HRT. The decision to use micronized progesterone vs a synthetic progestin, and transdermal vs oral estradiol, refines that profile further based on individual risk factors.

Start with the lowest effective estrogen dose (commonly 0.025 to 0.05 mg/day transdermal estradiol or 0.5 mg oral estradiol) and titrate to symptom control at 8 to 12 weeks.